Pathfinder Cell Therapy, Inc. - FORM 10-Q - EX-32.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C.1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002. - November 14, 2012

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Pathfinder Cell Therapy, Inc.Financial_Report.xls
EX-10.1 - PROMISSORY NOTES DATED AUGUST 17, OCTOBER 1 AND OCTOBER 23, 2012 ISSUED BY REGISTRANT IN FAVOR OF BREISGAU BIO VENTURES SA IN THE AGGREGATE PRINCIPAL AMOUNT OF $500,000. - Pathfinder Cell Therapy, Inc.f10q0912ex10i_pathfinder.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. - Pathfinder Cell Therapy, Inc.f10q0912ex31i_pathfinder.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. - Pathfinder Cell Therapy, Inc.f10q0912ex31ii_pathfinder.htm
EX-32.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C.1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002. - Pathfinder Cell Therapy, Inc.f10q0912ex32ii_pathfinder.htm
10-Q - QUARTERLY REPORT - Pathfinder Cell Therapy, Inc.f10q0912_pathfinder.htm
EXIBIT 32.1:  CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

         In connection with the accompanying Quarterly Report on Form 10-Q of Pathfinder Cell Therapy, Inc. for the quarter ended September 30, 2012, the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:

   (1)
such Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

   (2)
the information contained in such Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, fairly presents, in all material respects, the financial condition and results of operations of Pathfinder Cell Therapy, Inc.

Dated:  November 14, 2012
 
 /s/ Richard L. Franklin, M.D.    
     Name: Richard L. Franklin, M.D.   
    Title: CEO  
 
* A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided by Pathfinder Cell Therapy, Inc. and will be retained by Pathfinder Cell Therapy, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
 

Pathfinder Cell Therapy, Inc. Reports

Also read